Synthesis and biological evaluation of bis(methoxy-methyl)-7,8-dihydro-[1, 4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors

Archiv der Pharmazie

Volumn 338, Issue 10, 2005, Pages 502-505

  Lee, Yong Sup ^a   Seo, Seon Hee ^b   Yang, Beom Seok ^b   Lee, Jae Yeol ^a  

^a Kyung Hee University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

A431 cell; Antitumor; Dioxino 2,3 g quinazoline; EGFR enzyme; Inhibitor

Indexed keywords

3 IODOPHENYL GROUP; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 IODOANILINOQUINAZOLINE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIS(METHOXYMETHYL) 7,8 DIHYDRO [1,4]DIOXINO[2,3 G]QUINAZOLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PHENYL GROUP; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL STRAIN A431; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION;

CELL PROLIFERATION; ENZYME INHIBITORS; HCT116 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27644525153     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/ardp.200500126     Document Type: Article

References (19)

1. M. Yamada, T. Ikeuchi, H. Hatanaka, Prog. Neurobiol. 1997, 57, 19-37.
2. K. Hickey, D. Grehan, I. M. Reid, S. O'Briain, T. N. Walsh, T. P. J. Hennessy, Cancer 1994, 74, 1693-1698.
3. D. W. Fry, A. J. Kraker, A. McMichael, L. A. Ambrose, J. M. Nelson, W. R. Leopold, R. W. Connors, A. J. Bridges, Science 1994, 265, 1093-1095.
4. A. J. Bridges, H. Zhou, D. R. Cody, G. W. Rewcastle, A. McMichael, H. D. H. Showalter, D. W. Fry, A. J. Kraker, W. A. Denny, J. Med. Chem. 1996, 39, 267-276.
5. B. D. Palmer, T. Trumpp-Kallmeyer, D. W. Fry, J. M. Nelson, H. D. H. Showalter, W. A. Denny, J. Med. Chem. 1997, 40, 1519-529.
6. A. Wissner, D. M. Berger, D. H. Boschelli, M. B. Floyd Jr., L. M. Greenberger, B. C. Gruber, B. D. Johnson et al., J. Med. Chem. 2000, 43, 3244-3256.
7. J. B. Small, G. W. Rewcastle, J. A. Loo, K. D. Greis, O. H. Chan, E. I. Reyner, E. Lipka et al., J. Med. Chem. 2000, 43, 1380-1397.
8. H.-R. Tsou, N. Mamuya, B. D. Johnson, M. F. Reich, B. C. Gruber, F. Ye, R. Nilakantan et al., J. Med. Chem. 2001, 44, 2719-2734.
9. J. Y. Lee, Y. K. Park, S. H. Seo, I.-S. So, H.-K. Chung, B.-S. Yang, S. J. Lee, H. Park, Y. S. Lee, Arch. Pharm. Pharm. Med. Chem. 2001, 334, 357-360.
10. J. Y. Lee, Y. K. Park, S. H. Seo, B.-S. Yang, H. Park, Y. S. Lee, Arch. Pharm. Pharm. Med. Chem. 2002, 335, 487-494.
11. A. Bridges, J. Chem. Rev. 2001, 101, 2541-2571.
12. A. J. Barker, K. H. Gibson, W. Grundy, A. A. Godfrey, J. J. Barlow, M. P. Healy, J. R. Woodburn et al., Bioorg. Med. Chem. Lett. 2001, 11, 1911-1914.
13. J. Dowell, J. D. Minna, P. Kirkpatrick, Nat. Rev. Drug Discovery 2005, 4, 13-14.
14. R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas et al., J. Clin. Oncol. 2004, 22, 3238-3247.
15. M. W. Kunkel, K. E. Hook, C. T. Howard, S. Przybranowski, B. J. Roberts, W. L. Elliott, W. R. Leopold, Invest. New Drugs 1996, 13, 295-302.
16. A. G. Suárez, Tetrahedron Lett. 1999, 40, 3523-3526.
17. P. M. Heertjes, B. J. Knape, H. C. A. van Beek, K. van den Boogaart, J. Chem. Soc. 1957, 3445-3447.
18. S. Caddick, V. M. Delisser, V. E. Doyle, S. Khan, Tetrahedron 1999, 55, 2737-2754.
19. A. Wissner, M. B. Floyd, S. K. Rabindran, R. Nilakantan, L. M. Greenberger, R. Shen, Y.-F. Wang, H.-R. Tsou, Bioorg. Med. Chem Lett. 2002, 12, 2893-2897.